ADAR1 Capital Management »

Karyopharm Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.2k 1.5k 1.51

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Karyopharm Therapeutics

Vanguard Group
Eversept Partners
Palo Alto Investors
Adage Capital Partners GP
BlackRock
Citadel Advisors
Marshall Wace
Avidity Partners Management
Bnp Paribas Arbitrage, Snc
GSA Capital Partners
CAM Group Holding A/S
Jpmorgan Chase & Co
Geode Capital Management
Goldman Sachs Group
Deutsche Bank Aktiengesellschaft

View all funds holding Karyopharm Therapeutics